In last trading session, ProQR Therapeutics N.V (NASDAQ:PRQR) saw 0.4 million shares changing hands with its beta currently measuring 0.22. Company’s recent per share price level of $3.84 trading at $0.17 or 4.63% at ring of the bell on the day assigns it a market valuation of $396.30M. That closing price of PRQR’s stock is at a discount of -20.31% from its 52-week high price of $4.62 and is indicating a premium of 65.36% from its 52-week low price of $1.33. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.45 million shares which gives us an average trading volume of 1.36 million if we extend that period to 3-months.
For ProQR Therapeutics N.V (PRQR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProQR Therapeutics N.V (NASDAQ:PRQR) trade information
Upright in the green during last session for gaining 4.63%, in the last five days PRQR remained trading in the green while hitting it’s week-highest on Friday, 11/29/24 when the stock touched $3.84 price level, adding 3.27% to its value on the day. ProQR Therapeutics N.V’s shares saw a change of 93.94% in year-to-date performance and have moved 6.37% in past 5-day. ProQR Therapeutics N.V (NASDAQ:PRQR) showed a performance of 4.92% in past 30-days. Number of shares sold short was 0.41 million shares which calculate 0.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.75 to the stock, which implies a fall of -2.4% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would jump 47.92% in reaching the projected high whereas dropping to the targeted low would mean a gain of 47.92% for stock’s current value.
ProQR Therapeutics N.V (PRQR) estimates and forecasts
Statistics highlight that ProQR Therapeutics N.V is scoring comparatively higher than the scores of other players of the relevant industry. The company added 96.92% of value to its shares in past 6 months, showing an annual growth rate of 18.42% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 137.08% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7M for the same. And 2 analysts are in estimates of company making revenue of 9.07M in the next quarter. Company posted 6.79M and 5.02M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.74% during past 5 years.
ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders
PRIVIUM FUND MANAGEMENT B.V. is the top institutional holder at PRQR for having 5.58 million shares of worth $9.21 million. And as of 2024-06-30, it was holding 6.8416 of the company’s outstanding shares.
The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 3.63 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.4446 of outstanding shares, having a total worth of $6.02 million.
On the other hand, Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 620.0 shares of worth $2.38 million or 0.76% of the total outstanding shares. The later fund manager was in possession of 46.67 shares on Sep 30, 2024 , making its stake of worth around $0.18 million in the company or a holder of 0.06% of company’s stock.
